Osteoclast-derived exosomal miR-30a-3p promotes lead exposure-induced osteoporosis by triggering osteoblastic pyroptosis
Clinical Science · 2025
DOI: 10.1042/cs20243438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2025. Verfasst von Yue Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Occupational Disease Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Hauptthemen laut MEDLINE: MicroRNAs, Pyroptosis, Exosomes, Osteoporosis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation for Young Scientists of China, Natural Science Foundation of Jiangsu Province, Natural Science Foundation for Young Scientists of Jiangsu Province.
Abstract (Originalsprache)
High lead (Pb) burden in humans disrupts bone homeostasis and can induce osteoporosis. Here, we report that osteoclast-derived exosomes (OC-Exos) were enriched in the plasma of patients with low bone mineral density and Pb exposure. Osteoclasts (OCs) secrete microRNA-enriched exosomes, through which miR-30a-3p is transferred to osteoblasts (OBs) to induce pyroptosis, leading to the aggravation of bone loss. Mechanistically, OC-Exo-packaged miR-30a-3p triggered pyroptosis in OBs by stimulating the NLRP3 inflammasome, activating the caspase-1 pathway, and up-regulating the expression of IL-1 and IL-18. Depletion of miR-30a-3p abolished the effects of OC-Exo and alleviated the symptoms of Pb-induced osteoporosis. Collectively, our results suggest that miR-30a-3p is highly expressed in exosomes derived from OCs and mediates OB pyroptosis, inhibiting bone formation through cellular communication in Pb-induced osteoporosis. Therefore, OC-Exo-packaged miR-30a-3p may be a novel risk factor for Pb-induced osteoporosis and holds prognostic value in evaluating bone formation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Occupational Disease Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
- Jiangsu Province Engineering Research Center of Health Emergency, Nanjing 210009, China.
- Gulou District Center for Disease Control and Prevention, Nanjing 210003, China.
- Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, Kunming Medical University, Kunming 650500, China.
- College of Modern biomedical industry, Kunming Medical University, Kunming 650500, China.
- Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, China.
ORCID-Profile: Yue Gao, Tingting Yu, Hengdong Zhang, Ming Xu
Förderung
- National Science Foundation for Young Scientists of China
- Natural Science Foundation of Jiangsu Province
- Natural Science Foundation for Young Scientists of Jiangsu Province
- Program of Jiangsu Province Engineering Research Center of Health Emergency
- Youth General Program of Jiangsu Provincial Health Commission
Zitieren
APA
Gao, Y., Zhang, H., Jia, Y., Chen, Y., Wang, L., Ding, J., Wang, W., Zhu, B., Ouyang, L., He, X., An, Y., Yu, T., Zhang, H., & Xu, M. (2025). Osteoclast-derived exosomal miR-30a-3p promotes lead exposure-induced osteoporosis by triggering osteoblastic pyroptosis. Clinical Science. https://doi.org/10.1042/cs20243438
Vancouver
Gao Y, Zhang H, Jia Y, Chen Y, Wang L, Ding J, et al. Osteoclast-derived exosomal miR-30a-3p promotes lead exposure-induced osteoporosis by triggering osteoblastic pyroptosis. Clinical Science. 2025. doi:10.1042/cs20243438
BibTeX
@article{Gao2025,
author = {Gao, Yue and Zhang, Hang and Jia, Yinnong and Chen, Yuanfang and Wang, Luna and Ding, Jie and Wang, Wen and Zhu, Baoli and Ouyang, Liu and He, Xu and An, Yan and Yu, Tingting and Zhang, Hengdong and Xu, Ming},
title = {Osteoclast-derived exosomal miR-30a-3p promotes lead exposure-induced osteoporosis by triggering osteoblastic pyroptosis},
journal = {Clinical Science},
year = {2025},
doi = {10.1042/cs20243438}
}
EUVIMED